Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

The Cancer Institute of New Jersey, UMDNJ-RWJMS, New Brunswick NJ, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New Brunswick NJ
Treatments:ChemotherapyHospital:The Cancer Institute of New Jersey, UMDNJ-RWJMS
Drugs:Journal:Link
Date:Feb 2010

Description:

Patients:
This phase II trial involved 63 men with metastatic castration-resistant prostate cancer that were separated into 2 separate studies (arms). Arm A involved 32 of the men with a median age of 70 years (range 50-89). Arm B involved 31 men with a median age of 65 years (range 45-80).

Treatment:
Patients in Arm A were treated with a combination of the chemotherapy agents mitoxantrone, estramustine and vinorelbine.

Patients in Arm B received a combination of the biologic therapies 13-cis retinoic acid and interferon-alpha 2b, and the chemotherapy agent paclitaxel.

Toxicities:
The highest toxicity level reported for this study was grade 4, mostly in the form of neutropenia. Other toxicities included leucopenia and fatigue.

Results:
Median overall survival was 19.4 months for Arm A and 13.9 months for Arm B.

Correspondence: Dr. Robert S. DiPaola; email: [email protected]



Back